Cited by 687HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Open access

Wheeler, Deric L., Dunn, Emily F., Harari, Paul M.·2010·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2010.97PMC PMC2929287

Open this paper in CoChat — free account

Abstract

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis. EGFR has been strongly implicated in the biology of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas. Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized. In this Review, we provide a brief overview regarding the biology of EGFR, preclinical and clinical development of EGFR inhibitors, and molecular mechanisms that underlie the development of treatment resistance. A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2010.97

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877

Flagged first, then by citations

Show all 182 references

Sorted by citations

Items 401–500 of 687

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
Differential Transcriptional Effects of EGFR Inhibitors
Blumenberg, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102466 · Cited by 14
Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460
Choi, S. Y., Kim, H., Ryu, P. D., & Lee, S. Y. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0118-9 · Cited by 14
Endogenous thrombopoietin promotes non‐small‐cell lung carcinoma cell proliferation and migration by regulating EGFR signalling
Zou, Z., Fan, X., Liu, Y., Sun, Y., Zhang, X., Sun, G., Li, X., & Xu, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15314 · Cited by 15
Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239
Yan, T., GU, Y.-J., CAO, Z.-H., BIAN, X.-J., Lan, T., Sang, J., Jiang, L., Wang, Y., Qian, H., & Chen, Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.851 · Cited by 14
EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder
Alexander, R. E., Montironi, R., Antonio Lopez-beltran, B., Williamson, S. R., Wang, M., Post, K. M., Sen, J. D., Arnold, A. K., Zhang, S., Wang, X., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.132 · Cited by 15
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy
Gracia‐Cazaña, T., Salazar, N., Zamarrón, A., Mascaraque, M., Lucena, S. R., & Juarranz, Á. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2016.08.017 · Cited by 14
Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models
Ouyang, X., Barling, A. N., Lesch, A., Tyner, J. W., Choonoo, G., ZHENG, C. L., Jeng, S., West, T. M., Clayburgh, D. R., Courtneidge, S. A., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1451285 · Cited by 16
Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells
Yu, S.-Y., Liu, H.-F., Wang, S., Chang, C., Tsai, C.-M., & Chao, J. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.03.011 · Cited by 14
Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells
Kwon, I.-S., Hwang, Y.-N., Park, J., Na, H.-H., Kwon, T.-H., Park, J.-S., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316621 · Cited by 13
Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma
Williams, J. P., Kim, I., Ito, E., Shi, W., Yue, S., Siu, L. L., Waldron, J. N., O’Sullivan, B., Yip, K. W., & Liu, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098557 · Cited by 13
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
Simonelli, M., Zucali, P. A., Lorenzi, E., Rubino, L., Vincenzo, F. D., Sanctis, R. D., Perrino, M., Mancini, L. L., Tommaso, L. D., Rimassa, L., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.016 · Cited by 13
TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma
Shuai, S., Xiao, Y., Zhang, J., Kang, S., Chen, F., Luo, R., & Li, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.008 · Cited by 13
Metabolic Imaging Using Hyperpolarized Pyruvate–Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts
Mignion, L., Acciardo, S., Gourgue, F., Joudiou, N., Caignet, X., Goebbels, R., Corbet, C., Féron, O., Bouzin, C., Cani, P. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1369 · Cited by 13
Redefining disease
Bell, J. I. (2010) · Clinical Medicine · doi:10.7861/clinmedicine.10-6-584 · Cited by 12
Computer-Assisted Drug Discovery of a Novel Theobromine Derivative as an EGFR Protein-Targeted Apoptosis Inducer
Eissa, I. H., Yousef, R. G., Elkaeed, E. B., Alsfouk, A. A., Husein, D. Z., Ibrahim, I. M., El‐Mahdy, H. A., Elkady, H., & Metwaly, A. M. (2023) · Evolutionary Bioinformatics · doi:10.1177/11769343231217916 · Cited by 12
High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
Zhao, K., Wang, C., Fu, X., Cai, X., Wu, X., Hu, X., Fan, M., Xiang, J., Zhang, Y., Chen, H., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89592 · Cited by 12
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab
Wills, B., Cardona, A. F., Rojas, L., Ruíz-Patiño, A., Arrieta, O. G., Reguart, N., Carranza, H., Vargas, C. A., Otero, J. M., Corrales, L., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.12097 · Cited by 12
Mitochondrial Tumor Suppressors—The Energetic Enemies of Tumor Progression
Jakoubě, P., Cutano, V., González-Morena, J. M., & Keckesova, Z. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0518 · Cited by 13
Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer
Lee, A.-R., Lee, S., Shin, J. Y., Kim, J., Moon, K., & Jung, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-06621-w · Cited by 12
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
Foschi, F., Tinivella, A., Crippa, V., Pinzi, L., Mologni, L., Passarella, D., & Rastelli, G. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2145284 · Cited by 12
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors
Zhang, J., Jia, J., Zhu, F., Ma, X., Han, B., Wei, X., Tan, C., Jiang, Y., & Chen, Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25165e · Cited by 12
IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals
Ping, Y., Zhang, H., Deng, Y., Wang, L., Zhao, H., Pang, L., Fan, H., Xu, C., Li, F., Zhang, Y., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00289j · Cited by 11
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Looyenga, B. D., Cherni, I., MacKeigan, J. P., & Weiss, G. J. (2011) · Translational Oncology · doi:10.1593/tlo.10241 · Cited by 12
Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci
Roberto, D., Selvarajah, S., Park, P. C., Berman, D. M., & Venkateswaran, V. (2019) · The Prostate · doi:10.1002/pros.23903 · Cited by 12
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
Park, H., Williams, K. J., Trikalinos, N. A., Larson, S., Tan, B. R., Waqar, S. N., Suresh, R., Morgensztern, D., Tine, B. A. V., Govindan, R., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04183-0 · Cited by 12
Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments
Selzer, E., & Kornek, G. V. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.841540 · Cited by 12
Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer
Chang, H., Yang, C., Loi, L., Hung, C.-H., Wu, C., & Lin, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28406 · Cited by 13
Skin Cancer
Kurva, A., Korikani, M., Mohan, V., & Kancha, R. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-1802-3_21 · Cited by 12
Amphiregulin in Fibrotic Diseases and Cancer
Kim, T. R., Son, B., Lee, C. G., & Park, H.-O. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146945 · Cited by 11
Nanoscale Mapping of EGFR and c‑MET Protein Environments on Lung Cancer Cell Surfaces via Therapeutic Antibody Photocatalyst Conjugates
Robles, T. R., Olow, A., Bechtel, T. J., Lesley, S. A., Fadeyi, O., & Oslund, R. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00409 · Cited by 11
ALIX promotes cell migration and invasion of head and neck squamous cell carcinoma by regulating the expression of MMP9, MMP14, VEGF-C
Xie, Q., Wang, W., Yang, J., Xia, H.-F., Xiao, B.-L., Chen, G., Huang, J., Li, R., & Chen, G. (2023) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2023.105696 · Cited by 11
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model
Pagán, B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i44.4858 · Cited by 11
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor
Vigna, E., Pacchiana, G., Chiriaco, C., Cignetto, S., Fontani, L., Michieli, P., & Comoglio, P. M. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1079-0 · Cited by 11
Novel targeted therapies in head and neck cancer
Ferreira, M. B. A., Lima, J. P. D. S. N., & Cohen, E. E. W. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651455 · Cited by 11
Identification of subtype specific biomarkers of clear cell renal cell carcinoma using random forest and greedy algorithm
Wu, Y., Han, W., Xu, D., Wang, X., Yang, J., Lu, Z., Xu, C., & Ding, Y. (2021) · Biosystems · doi:10.1016/j.biosystems.2021.104372 · Cited by 11
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives
Tang, Z., Zha, L., Liang, R., & Li, T. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01778-7 · Cited by 11
Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
Glykofridis, I. E., Henneman, A. A., Balk, J. A., Haas, R. R. D. G., Westland, D., Piersma, S. R., Knol, J. C., Pham, T. V., Boekhout, M., Zwartkruis, F. J. T., et al. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100263 · Cited by 9
Hypoxic stabilization of RIPOR3 mRNA via METTL3-mediated m6A methylation drives breast cancer progression and metastasis
Xiong, J., Zhou, Z., Jiang, Y., Li, Q., Geng, Z., Guo, J., Yan, C., & Zhang, J. (2024) · Oncogene · doi:10.1038/s41388-024-03180-4 · Cited by 11
Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
Rajeeve, A. D., Yamuna, R., & Namboori, P. K. K. (2025) · Scientific Reports · doi:10.1038/s41598-024-83868-5 · Cited by 10
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
Ohishi, T., Kato, Y., Kaneko, M. K., Ohba, S., Inoue, H., Harakawa, A., & Kawada, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176037 · Cited by 10
The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients
Allegra, A., Salvo, E. D., Casciaro, M., Musolino, C., Pioggia, G., & Gangemi, S. (2020) · Biomedicines · doi:10.3390/biomedicines9010002 · Cited by 10
Detection of the Epidermal Growth Factor Receptor, Amphiregulin and Epiregulin in Formalin-Fixed Paraffin-Embedded Human Placenta Tissue by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging
Mahmoud, K. M., Cole, L. M., Newton, J., Mohamed, S., Al-Enazi, M. M., Quirke, P., & Clench, M. R. (2013) · European Journal of Mass Spectrometry · doi:10.1255/ejms.1212 · Cited by 10
Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway
Shao, J., Zheng, G., Chen, H., Liu, J., Xu, A., Chen, F., Li, T., Lu, Y., Xu, J., Zheng, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18640 · Cited by 10
Stat5 phosphorylation is responsible for the excessive potency of HB‐EGF
Heo, J., Kim, J. G., Kim, S., & Kang, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26639 · Cited by 10
Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review
Olatunji, I. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.10.038 · Cited by 10
Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Huang, W., Hsu, S.-C., Huang, S.-J., Chen, Y., Hsiao, Y.-C., Zhang, W., Fidler, I. J., & Hung, M. (2013) · Europe PMC (PubMed Central) · Cited by 10
Copolymeric Micelles for Delivery of EGCG and Cyclopamine to Pancreatic Cancer Cells
Sun, L., Zhang, C., & Li, P. (2014) · Nutrition and Cancer · doi:10.1080/01635581.2014.904908 · Cited by 10
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Zukin, M. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1590/s0104-42302012000200025 · Cited by 10
Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancer
Morris, L. G. T., & Chan, T. A.-T. (2011) · Oncotarget · doi:10.18632/oncotarget.407 · Cited by 10
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer
Iida, M., Crossman, B. E., Kostecki, K. L., Glitchev, C. E., Kranjac, C. A., Crow, M. T., Adams, J. M., Liu, P., Ong, I. M., Yang, D. T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105109 · Cited by 12
Self-citation
Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB
Kubaichuk, K. I., Seitz, T., Bergmann, U., Glumoff, V., Mennerich, D., & Kietzmann, T. (2024) · Oncogenesis · doi:10.1038/s41389-024-00538-x · Cited by 9
Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers
Eccles, S. A. (2012) · Frontiers in bioscience · doi:10.2741/4118 · Cited by 9
Alkannin exerts antitumor properties in cutaneous squamous cell carcinoma by inducing apoptosis and shifting the M1 / M2 polarization of tumor‐associated macrophages by upregulating PTEN
Zhang, Z., Wen, C., Jia, M., Zhang, H., & Sun, S. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12617 · Cited by 9
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
Burotto, M., Ali, S. A., & Coyne, G. O. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.973400 · Cited by 9
Transcriptional effects of inhibiting epidermal growth factor receptor in keratinocytes
Gazel, A., & Blumenberg, M. (2013) · Dermatologica Sinica · doi:10.1016/j.dsi.2012.11.003 · Cited by 9
Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation
Isobe, K., Kakimoto, A., MIKAMI, T., Kaburaki, K., Kobayashi, H., YOSHIZAWA, T., MAKINO, T., OTSUKA, H., Sano, G., Sugino, K., et al. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20010 · Cited by 9
Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma
Baker, L. C. J., Sikka, A., Price, J. M., Boult, J. K. R., Lepicard, E. Y., Box, G., Jamin, Y., Spinks, T. J., Krämer-Marek, G., Leach, M. O., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00271 · Cited by 9
The interaction between carcinoembryonic antigen‐related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer
Iwabuchi, E., Miki, Y., Kanai, A., Miyashita, M., Kijima, G., Hirakawa, H., Suzuki, T., Ishida, T., & Sasano, H. (2018) · The Journal of Pathology · doi:10.1002/path.5148 · Cited by 9
P130Cas Attenuates Epidermal Growth Factor (EGF) Receptor Internalization by Modulating EGF-Triggered Dynamin Phosphorylation
Kang, Y. S., Kim, W., Huh, Y. H., Bae, J., Kim, J.-S., & Song, W. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020125 · Cited by 9
Cell‐Surface Protein Labeling with Luminescent Nanoparticles through Biotinylation by Using Mutant β‐Lactamase‐Tag Technology
Yoshimura, A., Mizukami, S., Hori, Y., Watanabe, S., & Kikuchi, K. (2011) · ChemBioChem · doi:10.1002/cbic.201100021 · Cited by 9
The Soluble Heparin-Binding EGF-Like Growth Factor Stimulates EGF Receptor Trafficking to the Nucleus
Korotkevych, N. V., Labyntsev, A. J., Колибо, Д. В., & Комісаренко, С. В. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127887 · Cited by 9
Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives
Ye, G. H., Zhang, Y., He, M.-L., Yu, M.-Q., Li, S.-R., Du, B.-Q., Gao, Y., Gao, Y., & Ye, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117937 · Cited by 10
EGFR-Inhibition Enhances Apoptosis in Irradiated Human Head and Neck Xenograft Tumors Independent of Effects on DNA Repair
Stegeman, H., Span, P. N., Cockx, S. C., Peters, J. P. W., Rijken, P. F. J. W., van der Kogel, A. J., Kaanders, J. H. A. M., & Bussink, J. (2013) · Radiation Research · doi:10.1667/rr3349.2 · Cited by 8
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform
Bieberich, A. A., Laitinen, T., Maffuid, K., Fatig, R. O., Torrice, C., Morris, D. C., Crona, D. J., & Asquith, C. R. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-15552-5 · Cited by 9
Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study
Yang, H., Zhang, Z., Liu, Q., Yu, J., Liu, C., & Lu, W.-C. (2023) · Molecules · doi:10.3390/molecules28227607 · Cited by 8
Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
Lai, W., Chen, C., Yang, S., Wu, J., Chang, C.-J., Yang, P., & Peck, K. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.3 · Cited by 8
Low Phosphorylated AKT Expression in Laryngeal Cancer: Indications for a Higher Metastatic Risk
Nijkamp, M. M., Span, P. N., Stegeman, H., Grenman, R. A., Kaanders, J. H. A. M., & Bussink, J. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.046 · Cited by 8
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo
Ye, W., Zhou, F., Lin, Z., Shi, L., Huang, A., Liu, T., Yu, D., & Wu, G. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000597 · Cited by 8
Quantifying the phosphorylation timescales of receptor–ligand complexes: a Markovian matrix-analytic approach
López‐García, M., Nowicka, M., Bendtsen, C., Lythe, G., Ponnambalam, S., & Molina-Parı́s, C. (2018) · Open Biology · doi:10.1098/rsob.180126 · Cited by 8
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer
Wu, P.-F., Gao, W., Sun, C., Ma, T., & Hao, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000823 · Cited by 8
Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy
Huang, G., Chen, Q., Hu, J., Mao, J., He, Y., Bai, H., & Tang, G. (2021) · Biomaterials Science · doi:10.1039/d1bm01133b · Cited by 8
A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer
Wang, S., Hsu, Y.-P., Chang, C., Chan, Y., Chen, C., Wang, R.-H., Liu, K., Pan, P., Wu, Y., Yang, C., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114792 · Cited by 8
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy
Lin, P.-H., Tseng, C.-L., Cheng, Y.-C., Ho, C.-H., Chen, S. C., Wang, Y., Liu, E. W., Issafras, H., & Jiang, W. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1988072 · Cited by 7
Indications and pitfalls of immunohistochemistry in head and neck cancer
Caly, D. D. N., Viana, A., Rapoport, A., Dedivitis, R. A., Curioni, O. A., Cernea, C. R., & Brandão, L. G. (2013) · Brazilian Journal of Otorhinolaryngology · doi:10.5935/1808-8694.20130013 · Cited by 8
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel
Wein, A. N., Liu, S., Zhang, Y., McKenzie, A. T., & Leppla, S. H. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9847-1 · Cited by 8
The Molecular Basis for Novel Therapies
Hu, J. L., & Kesari, S. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182455187 · Cited by 8
18F-FLT PET changes during radio - therapy combined with cetuximab in head and neck squamous cell carcinoma patients
Troost, E. G. C., Bussink, J., van Herpen, C. M. L., Oyen, W. J. G., Kaanders, J. H. A. M., & Hoeben, B. A. W. (2014) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0625-13-09 · Cited by 8
Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice
Katsios, C. G., Ziogas, D. E., Liakakos, T., Zoras, O., & Roukos, D. H. (2010) · Journal of Surgical Research · doi:10.1016/j.jss.2010.10.038 · Cited by 8
METTL16-dependent GPX4 m6A modification links ferroptosis to NSCLC TKIs resistance
Zeng, Y., Wang, Q., Qiao, D., Dai, B., Wu, Y., Wang, M., Fan, Z., & Chen, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-14729-1 · Cited by 7
Gelatin Matrix as Functional Biomaterial for Immobilization of Nanoparticles of Metal-Containing Compounds
Mikhailov, O. V. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14020092 · Cited by 7
An afatinib-based theranostic fluorescent probe for cancer cells and its applications in monitoring pH changes during treatment
Wang, K., Wen, H., Liu, C., Li, Z., Wang, S., Zhu, H., Liu, M., Rong, X., Yu, M., Sheng, W., et al. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137056 · Cited by 7
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample
Feigelson, H. S., Zeng, C. X., Pawloski, P. A., Onitilo, A. A., Richards, C. S., Johnson, M., Kauffman, T. L., Webster, J., Nyirenda, C., Alexander, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094977 · Cited by 7
Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment
Möckelmann, N., Kriegs, M., Lőrincz, B., Busch, C., & Knecht, R. (2016) · Head and Neck · doi:10.1002/hed.24031 · Cited by 6
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3
Qiao, H., Zhao, D., Shi, H., Ren, K., Li, J., & Li, E. (2015) · Oncology Reports · doi:10.3892/or.2015.4140 · Cited by 7
Systems Biology and Integrative Omics in Breast Cancer
Lemus, E. H. (2014) · Springer eBooks · doi:10.1007/978-81-322-0843-3_17 · Cited by 7
Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models
Yang, F., Yang, L., Liu, B., You, J., & Zhou, Q. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.017 · Cited by 7
Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules
Arancillo, M., Taechalertpaisarn, J., Liang, X., & Burgess, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202015203 · Cited by 7
From Bench to Bedside: A Team’s Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Crossman, B. E., Harmon, R. L., Kostecki, K. L., McDaniel, N. K., Iida, M., Corday, L. W., Glitchev, C. E., Crow, M. T., Harris, M. A., Lin, C. Y., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206036 · Cited by 6
Self-citation
METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling
Sang, H., Liu, J., Chen, X., & Zeng, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14041-y · Cited by 6
c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
Min, W., He, C., Zhang, S., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602900 · Cited by 6
Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives
Fan, S., Kang, B., Li, S., Li, W., Chen, C., Chen, J., Deng, L., Chen, D., & Zhou, J. (2024) · Cell Cycle · doi:10.1080/15384101.2024.2366009 · Cited by 6
Panitumumab and Cetuximab Affect Differently Mirna Expression in Colorectal Cancer Cells
Chautard, R., Corset, L., Ibrahim, S., Desvignes, C., Paintaud, G., Baroukh, N., Guéguinou, M., Lecomte, T., & Raoul, W. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0520 · Cited by 6
KBTBD7 promotes non‐small cell lung carcinoma progression by enhancing ubiquitin‐dependent degradation of PTEN
Zou, Z., Zhang, B., Li, Z., Lei, L., Sun, G., Jiang, X., Guan, J., Zhang, Y., Xu, S., & Li, Q. (2022) · Cancer Medicine · doi:10.1002/cam4.4794 · Cited by 6
A Biodegradable Nucleotide Coordination Polymer for Enhanced NSCLC Therapy in Combination with Metabolic Modulation
Zhang, J., Li, X., Yin, Y., Cao, G., & Wang, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302187 · Cited by 6
Activated Protein Kinase C (PKC) Is Persistently Trafficked with Epidermal Growth Factor (EGF) Receptor
Heckman, C. A., Biswas, T., Dimick, D. M., & Cayer, M. L. (2020) · Biomolecules · doi:10.3390/biom10091288 · Cited by 6
Combination chemotherapy of cancer using the inhibitor of DNA methylation 5-aza-2'-deoxycytidine (decitabine)
Stephan, L., & Momparler, R. L. (2015) · Journal of Cancer Research & Therapy · doi:10.14312/2052-4994.2015-8 · Cited by 6
EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis
Williams, M., Lomberk, G. A., & Urrutia, R. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_15 · Cited by 6
Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer
Aboul‐Fettouh, N., Kubicki, S. L., Chen, L. L., Silapunt, S., & Migden, M. R. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.009 · Cited by 6
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
Stintzing, S., Zhang, W., Heinemann, V., Neureiter, D., Kemmerling, R., Kirchner, T., Jung, A., Folwaczny, M., Yang, D., Ning, Y., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0121 · Cited by 6

Authors: Wheeler, D. L., Dunn, E. F., & Harari, P. M.
Affiliations: University of Wisconsin–Madison (US)
Corresponding author: Wheeler, Deric L.
ORCID: Wheeler, Deric L.
Dunn, Emily F.
Harari, Paul M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2010-06-15
Volume: 7
Issue: 9
Pages: 493-507
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2010.97
PMC: PMC2929287
OpenAlex: W2053439872
Cited by: 683
References: 182
Citations by year: 2026: 21 · 2025: 20 · 2024: 35 · 2023: 29 · 2022: 31 · 2021: 29 · 2020: 44 · 2019: 25 · 2018: 36 · 2017: 50 · 2016: 46 · 2015: 61 · 2014: 66 · 2013: 68 · 2012: 64
FWCI: 6.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5t32ca009614-25)
U.S. Public Health Service (P30CAO14520)
National Cancer Institute (T-32 CA 0096-14, R01CA113448)
National Center for Research Resources (UL1RR025011)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: EGFR inhibitors, EGFR, acquired drug resistance, intrinsic resistance, tyrosine kinase inhibitors, resistance mechanisms, EGFR signaling, epithelial malignancies, lung cancer, head and neck cancer, colon cancer, pancreatic cancer, combination therapy
MeSH terms: Cetuximab, Erlotinib Hydrochloride, Gefitinib, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Proto-Oncogene Proteins, Quinazolines, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks